207 related articles for article (PubMed ID: 27119626)
1. Identification and Development of 2,3-Dihydropyrrolo[1,2-a]quinazolin-5(1H)-one Inhibitors Targeting Bromodomains within the Switch/Sucrose Nonfermenting Complex.
Sutherell CL; Tallant C; Monteiro OP; Yapp C; Fuchs JE; Fedorov O; Siejka P; Müller S; Knapp S; Brenton JD; Brennan PE; Ley SV
J Med Chem; 2016 May; 59(10):5095-101. PubMed ID: 27119626
[TBL] [Abstract][Full Text] [Related]
2. The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.
Vangamudi B; Paul TA; Shah PK; Kost-Alimova M; Nottebaum L; Shi X; Zhan Y; Leo E; Mahadeshwar HS; Protopopov A; Futreal A; Tieu TN; Peoples M; Heffernan TP; Marszalek JR; Toniatti C; Petrocchi A; Verhelle D; Owen DR; Draetta G; Jones P; Palmer WS; Sharma S; Andersen JN
Cancer Res; 2015 Sep; 75(18):3865-3878. PubMed ID: 26139243
[TBL] [Abstract][Full Text] [Related]
3. GNE-235: A Lead Compound Selective for the Second Bromodomain of PBRM1.
Cochran AG; Flynn M
J Med Chem; 2023 Sep; 66(18):13116-13134. PubMed ID: 37702400
[TBL] [Abstract][Full Text] [Related]
4. Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis.
Myrianthopoulos V; Gaboriaud-Kolar N; Tallant C; Hall ML; Grigoriou S; Brownlee PM; Fedorov O; Rogers C; Heidenreich D; Wanior M; Drosos N; Mexia N; Savitsky P; Bagratuni T; Kastritis E; Terpos E; Filippakopoulos P; Müller S; Skaltsounis AL; Downs JA; Knapp S; Mikros E
J Med Chem; 2016 Oct; 59(19):8787-8803. PubMed ID: 27617704
[TBL] [Abstract][Full Text] [Related]
5. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.
Wilson BG; Helming KC; Wang X; Kim Y; Vazquez F; Jagani Z; Hahn WC; Roberts CW
Mol Cell Biol; 2014 Mar; 34(6):1136-44. PubMed ID: 24421395
[TBL] [Abstract][Full Text] [Related]
6. GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1.
Taylor AM; Bailey C; Belmont LD; Campbell R; Cantone N; Côté A; Crawford TD; Cummings R; DeMent K; Duplessis M; Flynn M; Good AC; Huang HR; Joshi S; Leblanc Y; Murray J; Nasveschuk CG; Neiss A; Poy F; Romero FA; Sandy P; Tang Y; Tsui V; Zawadzke L; Sims RJ; Audia JE; Bellon SF; Magnuson SR; Albrecht BK; Cochran AG
J Med Chem; 2022 Aug; 65(16):11177-11186. PubMed ID: 35930799
[TBL] [Abstract][Full Text] [Related]
7. Selective and Cell-Active PBRM1 Bromodomain Inhibitors Discovered through NMR Fragment Screening.
Shishodia S; Nuñez R; Strohmier BP; Bursch KL; Goetz CJ; Olp MD; Jensen DR; Fenske TG; Ordonez-Rubiano SC; Blau ME; Roach MK; Peterson FC; Volkman BF; Dykhuizen EC; Smith BC
J Med Chem; 2022 Oct; 65(20):13714-13735. PubMed ID: 36227159
[TBL] [Abstract][Full Text] [Related]
8. Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains.
Crawford TD; Tsui V; Flynn EM; Wang S; Taylor AM; Côté A; Audia JE; Beresini MH; Burdick DJ; Cummings R; Dakin LA; Duplessis M; Good AC; Hewitt MC; Huang HR; Jayaram H; Kiefer JR; Jiang Y; Murray J; Nasveschuk CG; Pardo E; Poy F; Romero FA; Tang Y; Wang J; Xu Z; Zawadzke LE; Zhu X; Albrecht BK; Magnuson SR; Bellon S; Cochran AG
J Med Chem; 2016 Jun; 59(11):5391-402. PubMed ID: 27219867
[TBL] [Abstract][Full Text] [Related]
9. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
[TBL] [Abstract][Full Text] [Related]
10. Pan-SMARCA/PB1 Bromodomain Inhibitors and Their Role in Regulating Adipogenesis.
Wanior M; Preuss F; Ni X; Krämer A; Mathea S; Göbel T; Heidenreich D; Simonyi S; Kahnt AS; Joerger AC; Knapp S
J Med Chem; 2020 Dec; 63(23):14680-14699. PubMed ID: 33216538
[TBL] [Abstract][Full Text] [Related]
11. Novel structural-related analogs of PFI-3 (SRAPs) that target the BRG1 catalytic subunit of the SWI/SNF complex increase the activity of temozolomide in glioblastoma cells.
He Y; Yang C; Wang Y; Sacher JR; Sims MM; Pfeffer LM; Miller DD
Bioorg Med Chem; 2022 Jan; 53():116533. PubMed ID: 34863065
[TBL] [Abstract][Full Text] [Related]
12. Design and Synthesis of LM146, a Potent Inhibitor of PB1 with an Improved Selectivity Profile over SMARCA2.
Mélin L; Gesner E; Attwell S; Kharenko OA; van der Horst EH; Hansen HC; Gagnon A
ACS Omega; 2021 Aug; 6(33):21327-21338. PubMed ID: 34471737
[TBL] [Abstract][Full Text] [Related]
13. Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
Fish PV; Filippakopoulos P; Bish G; Brennan PE; Bunnage ME; Cook AS; Federov O; Gerstenberger BS; Jones H; Knapp S; Marsden B; Nocka K; Owen DR; Philpott M; Picaud S; Primiano MJ; Ralph MJ; Sciammetta N; Trzupek JD
J Med Chem; 2012 Nov; 55(22):9831-7. PubMed ID: 23095041
[TBL] [Abstract][Full Text] [Related]
14. SMARCA2-deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell lines.
Ehrenhöfer-Wölfer K; Puchner T; Schwarz C; Rippka J; Blaha-Ostermann S; Strobl U; Hörmann A; Bader G; Kornigg S; Zahn S; Sommergruber W; Schweifer N; Zichner T; Schlattl A; Neumüller RA; Shi J; Vakoc CR; Kögl M; Petronczki M; Kraut N; Pearson MA; Wöhrle S
Sci Rep; 2019 Aug; 9(1):11661. PubMed ID: 31406271
[TBL] [Abstract][Full Text] [Related]
15. Switch/sucrose nonfermenting nucleosome complex-deficient colorectal carcinomas have distinct clinicopathologic features.
Villatoro TM; Ma C; Pai RK
Hum Pathol; 2020 May; 99():53-61. PubMed ID: 32222462
[TBL] [Abstract][Full Text] [Related]
16. Switch/sucrose-non-fermentable (SWI/SNF) complex (SMARCA4, SMARCA2, INI1/SMARCB1)-deficient colorectal carcinomas are strongly associated with microsatellite instability: an incidence study in 4508 colorectal carcinomas.
Ahadi MS; Fuchs TL; Clarkson A; Sheen A; Sioson L; Chou A; Gill AJ
Histopathology; 2022 May; 80(6):906-921. PubMed ID: 34951482
[TBL] [Abstract][Full Text] [Related]
17. Structural ramification for acetyl-lysine recognition by the bromodomain of human BRG1 protein, a central ATPase of the SWI/SNF remodeling complex.
Singh M; Popowicz GM; Krajewski M; Holak TA
Chembiochem; 2007 Jul; 8(11):1308-16. PubMed ID: 17582821
[TBL] [Abstract][Full Text] [Related]
18. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
Soldi R; Ghosh Halder T; Weston A; Thode T; Drenner K; Lewis R; Kaadige MR; Srivastava S; Daniel Ampanattu S; Rodriguez Del Villar R; Lang J; Vankayalapati H; Weissman B; Trent JM; Hendricks WPD; Sharma S
PLoS One; 2020; 15(7):e0235705. PubMed ID: 32649682
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic and pharmacological control of pigmentation via Bromodomain Protein 9 (BRD9).
Basuroy T; Dreier M; Baum C; Blomquist T; Trumbly R; Filipp FV; de la Serna IL
Pigment Cell Melanoma Res; 2023 Jan; 36(1):19-32. PubMed ID: 36112085
[TBL] [Abstract][Full Text] [Related]
20. SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors.
Shorstova T; Marques M; Su J; Johnston J; Kleinman CL; Hamel N; Huang S; Alaoui-Jamali MA; Foulkes WD; Witcher M
Cancer Res; 2019 May; 79(10):2761-2774. PubMed ID: 30877105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
